2017
DOI: 10.1016/j.niox.2016.12.006
|View full text |Cite
|
Sign up to set email alerts
|

Beetroot juice versus chard gel: A pharmacokinetic and pharmacodynamic comparison of nitrate bioavailability

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
20
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 28 publications
(22 citation statements)
references
References 58 publications
1
20
0
Order By: Relevance
“…1); mechanisms underlying the hypotensive properties of beetroot is also most likely attributed to an enhancement of NO bioavailability as a result of increased non-enzymatic reduction of NO 3 into NO 2 and NO [36,50]. The pharmacokinetics of NO 3 are suggested to differ based on the delivery vehicle [51,52], in which beetroot was used as in the vast majority of clinical studies, investigating the hypotensive effect of NO 3 [26,31,35,[50][51][52]. The non-significant blood pressure lowering effect of NO 3 -depleted beetroot compared to NO 3 -rich beetroot [32,41], may imply the key and potential role of NO 3 versus other beetroot's nutraceuticals.…”
Section: Effects Of Beetroot On Blood Pressure and Vascular Functionmentioning
confidence: 99%
“…1); mechanisms underlying the hypotensive properties of beetroot is also most likely attributed to an enhancement of NO bioavailability as a result of increased non-enzymatic reduction of NO 3 into NO 2 and NO [36,50]. The pharmacokinetics of NO 3 are suggested to differ based on the delivery vehicle [51,52], in which beetroot was used as in the vast majority of clinical studies, investigating the hypotensive effect of NO 3 [26,31,35,[50][51][52]. The non-significant blood pressure lowering effect of NO 3 -depleted beetroot compared to NO 3 -rich beetroot [32,41], may imply the key and potential role of NO 3 versus other beetroot's nutraceuticals.…”
Section: Effects Of Beetroot On Blood Pressure and Vascular Functionmentioning
confidence: 99%
“…Gas-phase chemiluminescence was used to determine plasma [NO 3 − ] and [NO 2 − ], as previously described (Pinder et al 2008 ; Muggeridge et al 2014 ; McIlvenna et al 2017 ). Briefly, following the creation of a standard curve at several concentrations (0–1000 nM for NO 2 − ) and (0–100 µM for NO 3 − ), samples were thawed in a water bath at 37 °C for 3 min.…”
Section: Methodsmentioning
confidence: 99%
“…Several studies have demonstrated that increasing plasma levels of NO 3 − and NO 2 − through dietary NO 3 − ingestion and via sunlight exposure can reduce blood pressure (BP) (Larsen et al 2006 ; Webb et al 2008 ; Opländer et al 2009 ; Kapil et al 2010 ; Vanhatalo et al 2010 ; Siervo et al 2013 ; Wylie et al 2013 ; Muggeridge et al 2015 ; McIlvenna et al 2017 ). Increasing the circulating concentration of NO metabolites has also been shown to elicit other cardiovascular and metabolic effects, including the reduction of resting oxygen utilization ( ) (Larsen et al 2014 ; Whitfield et al 2016 ).…”
Section: Introductionmentioning
confidence: 99%
“…In each trial, participants initially lay supine for 15 min prior to obtaining a venous blood sample by venepuncture to ensure values were not influenced by postural changes 20 . Samples were collected in a vacutainer containing EDTA and spun immediately in a centrifuge for 10 min at 4000 rpm and 4 o C before the plasma was extracted and frozen at -80 o C. Plasma samples were later analysed for plasma [NO3 -] and [NO2 -] via gasphase chemiluminescence using methods previously described in detail 21 . A second venous blood sample was obtained immediately after completion of the IPC protocol in the PLA+IPC and NIT+IPC trials to determine the effects of IPC on NO2and NO3concentration.…”
Section: Accepted Manuscriptmentioning
confidence: 99%